Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HEC74647 · 1 trial · 1 indication
Incidence of adverse events
Maximum plasma concentration of study drugs
Maximum plasma concentration of study drugs
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | Subjects will receive HEC74647 on Day 1\~7 and Day13\~19, co-administration with HEC110114 on Day13\~19. |
| Part B | EXPERIMENTAL | Subjects will receive HEC110114 on Day 1\~7 and Day13\~19, co-administration with HEC74647 on Day13\~19. |
| Name | Type | Description |
|---|---|---|
| HEC74647 | DRUG | Administered HEC74647 200 mg orally once daily in fed state |
| HEC110114 | DRUG | Administered HEC110114 800 mg orally once daily in fed state |
Inclusion Criteria: * Sign the informed consent form before the trial and fully understand the contents of the trial, the process and possible adverse reactions. * Be able to complete the study according to the trail protocol. * Subjects (including partners) have no pregnancy plan within 3 months a...
HEC74647 is an investigational small molecule being developed for the treatment of chronic Hepatitis C. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied as a potential therapy for this infectious disease.
HEC74647 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol SBFM. The company is advancing this small molecule through clinical development for the treatment of chronic Hepatitis C.
HEC74647 is currently in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The Phase 1 trial has been completed, and the drug remains in the early stages of clinical testing for chronic Hepatitis C.
HEC74647 has one completed Phase 1 clinical trial registered under NCT04232514. This study was a drug-drug interaction trial between HEC74647PA capsules and HEC110114 tablets in healthy subjects. The trial enrolled 28 participants and was conducted in China.
HEC74647 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of chronic Hepatitis C. The drug has not yet completed the clinical trials required for regulatory approval and remains under investigation.